EdiGene Forms Translational Stem Cell Collaboration with Haihe Lab

EdiGene, a Beijing gene-editing company, announced a translational R&D collaboration with the Haihe Laboratory of Cell Ecosystem to develop hematopoietic stem cell regenerative therapies and a platform technology. The Haihe Lab focuses on fundamental research and translation in the cell ecosystem. Under the agreement, both parties will work together to develop hematopoietic stem cell regenerative therapies, novel genetically-modified hematopoietic stem cell therapies and innovative biomarkers for quality control of stem cell production. EdiGene has started China trials of its lead candidate, the first gene-edited hematopoietic stem cell therapy approved for China tests. More details....

Share this with colleagues: